PR Log (Press Release) – May 11, 2010 – Research Triangle Park, NC – Catalent Pharma Solutions’ industry experts will deliver scientific poster presentations this month at the 2010 AAPS National Biotechnology Conference, May 16-19 in San Francisco, California. This week of educational programming is dedicated to advancing health through innovations in biotherapeutics. Catalent is a sustaining sponsor of the 2010 AAPS National Biotechnology Conference.
Catalent biotechnology industry experts will present a total of four scientific posters for conference attendees. The presentations include:
Simone S. Cummings, Ph.D., Gwendolyn M. Wise-Blackman, Ph.D. will present “Overcoming Assay Drift and Multiple Matrix Interference Challenges in a PK ELISA.”
Poster Session: Tuesday, May 18, 11:00 AM – 6:00 PM.
Meet the author: 5:00 to 6:00 PM. Dr. Joseph J. Lundquist, Ph.D., Ana T. Menendez, Ph.D. will present “A Novel High-Throughput Method for the Separation of a Derivatized Therapeutic Protein from Its Unmodified Form in Serum.”
Poster Session: Monday, May 17, 11:00 AM – 6:00 PM.
Meet the author: 5:00 – 6:00 PM. Ana Menendez, Ph.D. will present “Standardizing Phase Appropriate Validation of GMP Potency Bioassays.”
Poster Session: Wednesday, May 19, 8:00 AM – 2:00 PM.
Meet the author: 1:00 PM – 2:00 PM. Valerie A. Stratico, M.S., Ana T. Menendez, Ph.D., and Dr. Gwendolyn M. Wise-Blackman, Ph.D. will present “Overcoming Free Drug and Matrix Effects in Detecting Antibodies to a Pegylated Protein.”
Poster Session: Wednesday, May 19, 8:00 AM – 2:00 PM.
Meet the author: 1:00 PM – 2:00 PM. Catalent possesses a diverse and highly integrated portfolio of biotechnology directed services designed to facilitate development from late target discovery and pre-clinical evaluation through clinical scale manufacturing in fill and finish of liquid or lyophilized biopharmaceutical drugs. For more information on Catalent’s biopharmaceutical development services, go to http://www.catalent.com/development. About Catalent Headquartered in Somerset, New Jersey, Catalent is one of the leading providers of advanced dose form and packaging technologies, and development, manufacturing, packaging and printing services for pharmaceutical, biotechnology and consumer healthcare companies in nearly 100 countries. Catalent applies its local market expertise and technical creativity to advance treatments, change markets and enhance patient outcomes. Catalent employs approximately 9,100 at 30 facilities worldwide and in fiscal 2009 generated more than $1.6 billion of annual revenue. For more information, visit http://www.catalent.com.
Meet the author: 5:00 to 6:00 PM. Dr. Joseph J. Lundquist, Ph.D., Ana T. Menendez, Ph.D. will present “A Novel High-Throughput Method for the Separation of a Derivatized Therapeutic Protein from Its Unmodified Form in Serum.”
Poster Session: Monday, May 17, 11:00 AM – 6:00 PM.
Meet the author: 5:00 – 6:00 PM. Ana Menendez, Ph.D. will present “Standardizing Phase Appropriate Validation of GMP Potency Bioassays.”
Poster Session: Wednesday, May 19, 8:00 AM – 2:00 PM.
Meet the author: 1:00 PM – 2:00 PM. Valerie A. Stratico, M.S., Ana T. Menendez, Ph.D., and Dr. Gwendolyn M. Wise-Blackman, Ph.D. will present “Overcoming Free Drug and Matrix Effects in Detecting Antibodies to a Pegylated Protein.”
Poster Session: Wednesday, May 19, 8:00 AM – 2:00 PM.
Meet the author: 1:00 PM – 2:00 PM. Catalent possesses a diverse and highly integrated portfolio of biotechnology directed services designed to facilitate development from late target discovery and pre-clinical evaluation through clinical scale manufacturing in fill and finish of liquid or lyophilized biopharmaceutical drugs. For more information on Catalent’s biopharmaceutical development services, go to http://www.catalent.com/development. About Catalent Headquartered in Somerset, New Jersey, Catalent is one of the leading providers of advanced dose form and packaging technologies, and development, manufacturing, packaging and printing services for pharmaceutical, biotechnology and consumer healthcare companies in nearly 100 countries. Catalent applies its local market expertise and technical creativity to advance treatments, change markets and enhance patient outcomes. Catalent employs approximately 9,100 at 30 facilities worldwide and in fiscal 2009 generated more than $1.6 billion of annual revenue. For more information, visit http://www.catalent.com.
